DE69429173T2 - Taxolderivate - Google Patents

Taxolderivate

Info

Publication number
DE69429173T2
DE69429173T2 DE69429173T DE69429173T DE69429173T2 DE 69429173 T2 DE69429173 T2 DE 69429173T2 DE 69429173 T DE69429173 T DE 69429173T DE 69429173 T DE69429173 T DE 69429173T DE 69429173 T2 DE69429173 T2 DE 69429173T2
Authority
DE
Germany
Prior art keywords
taxol derivatives
formula
taxol
ch2opo3
ch2oso3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69429173T
Other languages
English (en)
Other versions
DE69429173D1 (en
Inventor
Larry L Klein
Clarence J Maring
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of DE69429173D1 publication Critical patent/DE69429173D1/de
Application granted granted Critical
Publication of DE69429173T2 publication Critical patent/DE69429173T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
DE69429173T 1993-07-15 1994-07-15 Taxolderivate Expired - Fee Related DE69429173T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/092,124 US5468769A (en) 1993-07-15 1993-07-15 Paclitaxel derivatives
PCT/US1994/007973 WO1995002400A1 (en) 1993-07-15 1994-07-15 Taxol derivatives

Publications (2)

Publication Number Publication Date
DE69429173D1 DE69429173D1 (en) 2002-01-03
DE69429173T2 true DE69429173T2 (de) 2002-07-04

Family

ID=22231738

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69429173T Expired - Fee Related DE69429173T2 (de) 1993-07-15 1994-07-15 Taxolderivate

Country Status (8)

Country Link
US (1) US5468769A (de)
EP (1) EP0708642B1 (de)
JP (1) JPH09500138A (de)
AT (1) ATE209034T1 (de)
CA (1) CA2165079A1 (de)
DE (1) DE69429173T2 (de)
ES (1) ES2168304T3 (de)
WO (1) WO1995002400A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990325A (en) * 1993-03-05 1999-11-23 Florida State University Process for the preparation of 9-desoxotaxol, 9-desoxobaccatin III and analogs thereof
US5973160A (en) 1992-12-23 1999-10-26 Poss; Michael A. Methods for the preparation of novel sidechain-bearing taxanes
ATE502664T1 (de) 1993-07-19 2011-04-15 Angiotech Pharm Inc Herstellungsmethode eines stents mit anti- angiogener zusammensetzung
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
CN1304058C (zh) 1996-03-12 2007-03-14 Pg－Txl有限公司 水溶性紫杉醇产品
US5635531A (en) * 1996-07-08 1997-06-03 Bristol-Myers Squibb Company 3'-aminocarbonyloxy paclitaxels
AU4768797A (en) 1996-10-24 1998-05-15 Institute Armand-Frappier A family of canadensol taxanes, the semi-synthetic preparation and therapeutic use thereof
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US20020077290A1 (en) * 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
PL366100A1 (en) * 2000-09-22 2005-01-24 Bristol-Myers Squibb Company Method for reducing toxicity of combined chemotherapies
US7211562B2 (en) 2000-11-02 2007-05-01 Sloan-Kettering Institute For Cancer Research Methods for enhancing the efficacy of cytotoxic agents through the use of HSP90 inhibitors
JP2006513152A (ja) * 2002-10-09 2006-04-20 ファイトジェン ライフ サイエンシズ インコーポレイテッド 新規タキサンならびにその使用および調製に関する方法
ES2537514T3 (es) 2003-04-04 2015-06-09 Incyte Corporation Composiciones, métodos y kits relacionados con la escisión de HER-2
US7202370B2 (en) * 2003-10-27 2007-04-10 Conor Medsystems, Inc. Semi-synthesis of taxane intermediates from 9-dihydro-13-acetylbaccatin III
USH2260H1 (en) 2005-02-17 2011-07-05 Angiotech International Ag Stents combined with paclitaxel derivatives
WO2008082487A2 (en) 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
AU2010300925A1 (en) 2009-09-30 2012-03-29 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
EP2608672B1 (de) 2010-08-23 2020-12-16 Syntrix Biosystems, Inc. Aminopyridin- und aminopyrimidincarboxamide als cxcr2-modulatoren
MX359556B (es) 2013-08-02 2018-10-02 Syntrix Biosystems Inc Acido 2-[5-[n-(4-fluorofenil)carbamoíl]pirimidin-2-ilsulfanilmetil ]-4-(trifluorometoxi)fenil]borónico.
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
MX2022003396A (es) 2019-09-19 2022-04-19 Leap Therapeutics Inc Uso de inhibidores de dkk-1 para tratar el cancer.
KR20220131223A (ko) 2019-11-22 2022-09-27 리프 테라퓨틱스 인코포레이티드 Dkk-1 억제제를 사용하여 암을 치료하는 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
DK0639186T3 (da) * 1992-04-17 1999-12-13 Abbott Lab Taxolderivater

Also Published As

Publication number Publication date
EP0708642A4 (de) 1996-03-12
CA2165079A1 (en) 1995-01-26
ES2168304T3 (es) 2002-06-16
EP0708642A1 (de) 1996-05-01
DE69429173D1 (en) 2002-01-03
WO1995002400A1 (en) 1995-01-26
ATE209034T1 (de) 2001-12-15
US5468769A (en) 1995-11-21
EP0708642B1 (de) 2001-11-21
JPH09500138A (ja) 1997-01-07

Similar Documents

Publication Publication Date Title
ATE209034T1 (de) Taxolderivate
AU1608692A (en) Amidinophenylalanine derivatives, a process for the preparation thereof, use thereof and agents containing these as anticoagulants
RU2088589C1 (en) Derivatives of 17 beta-substituted-4-aza-5-5 alpha-androstane-3-ones, methods of synthesis of compounds, pharmaceutical composition, compound 4
SE9203825L (sv) Dubbelt verkande inhibitorer foer no-syntas och cyklooxygenas, foerfarande foer framstaellning daerav och terapeutiska kompositioner innehaallande desamma
ES2081120T3 (es) Procedimiento para la preparacion de derivados de la bacatina iii y la desacetil-10 bacatina iii.
HUT61555A (en) Process for producing 2,8-dioxa-bicyclo/3.2.1/octane derivatives and pharmaceutical compositions comprising same
DE69213546T2 (de) Neue Peptid-Verbindungen und Verfahren zur Herstellung davon
FI935800A0 (fi) Antidepressiva och mot Parkisons sjukdom verksamma foereningar
KR960703863A (ko) 암 치료용 신규 비스-나프탈이미드(New Bis-naphthalimides for the Treatment of Cancer)
CA2087004A1 (en) Tropolone derivatives and pharmaceutical composition thereof for preventing and treating ischemic diseases
DE69330601T2 (de) Serotoninergische ergolin derivate
IL108665A (en) Pharmaceutical compositions containing ureido derivatives of substituted pyrroles, certain such novel compounds and their preparation
FI944040A0 (fi) Laktolijohdannaiset, niiden valmistus ja käyttö
HUT70761A (en) Alkyl derivatives of trazodone having action for central nervous system, pharmaceutical compositions for preparing thereof
ATE100463T1 (de) Renin-hemmende aminooligohydroxy-derivate.
SE9203824L (sv) Bensofuranylimidazol-derivat, foerfarande foer framstaellning daerav och terapeutiska kompositioner innehaallande desamma
ES8201993A1 (es) Un procedimiento para la preparacion de tiazoles
ES528459A0 (es) Procedimiento de preparacion de nuevos derivados 1-hidroxipropil resorcinos provistos de un grupo fenilo sustituidos.
SE8903313L (sv) Nya 2-metoxikarbonyl-substituerade n,n'-di-(trimetoxibensoyl)-piperaziner, foerfarande foer framstaellning daerav och terapeutiska foereningar innehaallande dem
DE69528984T2 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
ES2079997A1 (es) Compuestos de fenil fenol sustituidos antagonistas de leucotrieno, procedimiento para su obtencion y formulaciones farmaceuticas de los mismos.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee